Novel techniques of percutaneous sonography-guided surgical operations (SonoSurgery

一家瑞士公司Spirecut开发了一种创新的方法来治疗腕管和扳机指，使用专利仪器（Sono-Instruments）和在超声下进行的无切口技术。患者可以在10分钟内在门诊接受治疗，无需缝合，并可以立即恢复正常活动。在目前的环境下，NHS资源面临巨大压力，常规手术的等待名单不断增加（NHS等待名单上有超过700万人），这种新技术有可能降低成本，提高NHS效率，让患者更快地重返工作岗位，帮助经济摆脱新冠肺炎。在这个项目中，一个英国-瑞士合作团队将致力于将Spirecut方法扩展到其他患者群体。Sono-Instruments的英国分销商、Sovereign Medical和南安普顿大学的健康经济学家将与瑞士的Spirecut合作，研究将该技术扩展到其他疾病，如Dupuytren病、De Quervain和网球肘。Sovereign Medical将牵头招募英国-瑞士联合专家顾问小组，包括骨科医生和介入放射科医生，他们将评估Spirecut技术在这些额外用途中的适用性。咨询小组的讨论和咨询将通过德尔菲法与更广泛的临床医生进行，以评估潜在适应症的技术可行性，以及采用这些技术对卫生服务和医疗创新的经济影响。南安普顿的卫生经济团队将开发一个模型，以帮助进一步研究和投资的决策。该模型将从商业角度提供每种适应症的市场价值估计值，并估计NHS的预算影响和成本效益。这些估计值将基于已发表的信息、真实世界证据来源和专家意见，并将在瑞士临床研究结果可用时更新。这将为今后向国家健康和护理卓越研究所（NICE）提交报告奠定基础，目的是获得NHS采用的建议。

A Swiss company, Spirecut, has developed an innovative way to treat carpal tunnel and trigger finger using patented instruments (Sono-Instruments) and an incisionless technique conducted under ultrasound. Patients can be treated in an outpatient clinic in under 10 minutes, with no stitches and can resume normal activities immediately. In the current climate, with great strain on NHS resources and growing waiting lists for routine operations (over 7 million on NHS waiting list), this novel technique has the potential to reduce costs, improve NHS efficiency and get patients back to work faster, helping the economy post Covid. In this project, a collaborative UK-Swiss team will work to extend the Spirecut approach to other patient groups.The UK distributor of the Sono-Instruments, Sovereign Medical and health economists at the University of Southampton will work in partnership with Spirecut in Switzerland to conduct research on the extension of this technology for other conditions, such as Dupuytren disease, De Quervain and tennis elbow. Sovereign Medical will lead on recruiting to a joint UK-Swiss panel of expert advisors, including orthopaedic surgeons and interventional radiologists, who will assess suitability of the Spirecut technology these additional uses. The advisory group deliberations and consultations with a wider group of clinicians in a Delphi exercise will be used to assess the technical feasibility of the potential indications, and the economic impact that adopting these techniques would have on health services and medical innovation.The health economic team at Southampton will develop a model to aid decision making about further research and investment. The model will provide estimates of market value for each indication from a commercial perspective and estimates of budget impact and cost-effectiveness for the NHS. These estimates will be based on published information, real-world evidence sources and expert opinion, and will be updated as results from the Swiss clinical studies become available. This will provide a foundation for a future submission to the National Institute for Health and Care Excellence (NICE) with the aim of obtaining a recommendation for NHS adoption.